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Abstract
Background: Human MCF-7 cells have been studied extensively as a model for breast cancer cell
growth. Many reports have established that serum-starved MCF-7 cells can be induced to
proliferate upon the sole addition of 17β-estradiol (E2). However, the extent of the mitogenic
response to E2 varies in different MCF-7 strains and may even be absent. In this study we compared
the E2-sensitivity of three MCF-7 laboratory strains.
Results: The MCF-7S line is non-responsive to E2, the MCF-7 ATCC has an intermediate response
to E2, while the MCF-7 NKI is highly E2-sensitive, although the levels and activities of the estrogen
receptor (ER) are not significantly different. Both suramin and IGF type I receptor blocking
antibodies are able to inhibit the mitogenic response to E2-treatment in MCF-7 ATCC and MCF-
7 NKI cells. From this we conclude that E2-induced proliferation is dependent on IGF type I
receptor activation in all three MCF-7 strains.
Conclusions: The results presented in this article suggest that E2-responsiveness of MCF-7 cells
is dependent on the secretion of an autocrine factor activating the IGF-IR. All three strains of MCF-
7 breast cancer cells investigated do not respond to E2 if the IGF-RI-pathway is blocked. Generally,
breast cancer therapy is targeted at inhibiting estrogen action. This study suggests that inhibition of
IGF-action in combination with anti-estrogen-treatment may provide a more effective way in
treatment or even prevention of breast cancer.
Background
Clinical studies have shown that therapeutic agents pre-
venting the synthesis and actions of estrogens are highly
successful in the treatment of breast cancer. The mecha-
nisms by which estrogens stimulate cell proliferation,
however, are still not clear. The epithelial breast cancer
derived MCF-7 cell line is one of the most frequently used
model systems. Many groups have reported that addition
of E2 to the medium of these cells induces a proliferative
response [1–5]. However, a comparison of different labo-
ratory strains of MCF-7 reveals that the degree of stimula-
tion differs, and may even be absent [6–9].
Recently, we have demonstrated that E2 does not induce
cell proliferation in the MCF-7S cell line under serum-free,
steroid hormone-free conditions. However, E2 in
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synergism with submitogenic concentrations of insulin-
like growth factor I (IGF-I; 2 ng/ml) does induce a prolif-
erative response, comparable to the response to mitogenic
amounts of IGF-I (20 ng/ml) [10]. We have found that
both E2 and mitogenic amounts of IGF-I strongly induce
cyclin D1 expression, whereas submitogenic amounts of
IGF-I do not significantly elevate cyclin D1 levels. IGF-I,
but not E2, is able to activate PI3-kinase, which leads to
inhibition of GSK3β activity. Here, a per se non-mitogenic
amount of IGF-I suffices. Inhibition of GSK3β triggers
nuclear accumulation of the cyclin D1, but only if cyclin
D1 levels are strongly induced concomitantly, which is
effectuated by E2. After cyclin D1 accumulates in the
nucleus, activation of the cyclin D1/CDK4 complex and
subsequent cell cycle progression is observed [11].
In contrast to other laboratory MCF-7 strains, MCF-7S
cells are almost completely growth arrested in G0/G1
phase of the cell cycle by serum deprivation in estrogen-
free medium, without the need for estrogen antagonists or
other inhibitors to reach quiescence. Other laboratory
strains of MCF-7 proliferate well when E2 is added after
serum-deprivation. In the present study, we compare
three distinct MCF-7 strains to determine the cause of
their differences in sensitivity for E2. The MCF-7S cell line
is non-responsive to E2. The MCF-7 cell line from the
American Type Culture Collection (referred to as "MCF-7
ATCC") shows an intermediate E2-response. The MCF-7
line obtained from the Dutch Cancer Institute in Amster-
dam, The Netherlands (referred to as "MCF-7 NKI") is
highly E2-responsive.
Results
Three MCF-7 strains exhibit differences in E2-
responsiveness
The E2-responsiveness of the three MCF-7 strains was
measured and compared to their response to IGF-I in a
DNA-synthesis assay. The cells were seeded in 24-well
plates in steroid- and serum-free medium. After 26 h, 1
nM E2, 20 ng/ml of IGF-I (I(20)), 2 ng/ml of IGF-I (I(2)) or
the combination of 1 nM E2 and 2 ng/ml of IGF-I (I(2)E2)
were added. Twenty-four h later, 3H-thymidine (3H-TdR)
was added for a 6 h period, after which the cells were har-
vested. Figure 1 shows the 3H-TdR incorporation in the
MCF-7 cell lines, normalized to 3H-TdR incorporation
induced by 20 ng/ml of IGF-I. A small amount of 3H-TdR
is incorporated in untreated serum-starved MCF-7S cells,
approximately 1% of the incorporation induced by 20 ng/
ml of IGF-I. The MCF-7 ATCC and the MCF-7 NKI cells
show higher 3H-TdR incorporation values in untreated
serum-starved cells, 6 and 12% of the 20 ng/ml IGF-I
value, respectively. This indicates that these cells are less
well synchronized by serum- and steroid-deprivation and
may need additional treatment to reach quiescence. In
MCF-7S cells, only a moderate increase in 3H-TdR incor-
poration is induced by stimulation with either 2 ng/ml of
IGF-I or 1 nM E2 in MCF-7S cells, to 3 and 9% of the IGF-
I (20 ng/ml) value respectively. When both IGF-I (2 ng/
ml) and E2 are added, a strong increase in 3H-TdR incor-
poration is observed to 88% of the incorporation level of
20 ng/ml of IGF-I. Thus, a clear synergism of E2 and IGF-
I on the induction of DNA-synthesis in MCF-7S cells is
demonstrated. In MCF-7 ATCC cells, the 3H-TdR incorpo-
ration induced by 2 ng/ml of IGF-I is much higher (26%
of the incorporation seen with 20 ng/ml of IGF-I) than in
MCF-7S cells. Also 1 nM E2 induces a much larger increase
in incorporation (40%) when compared to the incorpora-
tion in MCF-7S cells. However, the combination of the
two still is synergistic, resulting in a higher incorporation
level (115%) than the added effect of the two hormones
individually (66%). In MCF-7 NKI cells, E2 is an even
stronger inducer of 3H-TdR incorporation. In this MCF-7
strain, addition of E2 results in a higher incorporation
level than observed with mitogenic amounts of IGF-I. No
synergy between IGF-I and E2 can be observed in MCF-7
NKI, since 3H-TdR incorporation induced by 1 nM E2 by
itself is as high as by the combination of IGF-I (2 ng/ml)
and 1 nM E2.
The three MCF-7 strains express ERα and show E2-
responsive cyclin D1 gene expression
To investigate whether MCF-7 ATCC and MCF-7 NKI
express higher levels of ERα than MCF-7S, we analyzed
the ERα content of serum-starved MCF-7S, MCF-7 ATCC,
and MCF-7 NKI cells by Western blotting. We find that the
level of ERα expression in MCF-7S and MCF-7 NKI are
comparable, whereas the MCF-7 ATCC express slightly
higher levels of ERα (figure 2A). The observed difference
in expression levels does not correlate with E2 inducible
proliferation in the three strains of MCF-7.
In order to detect differences in functionality of the ER, we
analyzed the expression level of an E2-responsive gene,
cyclin D1, in untreated serum-starved and in E2-treated
cells. Like in MCF-7S cells, E2 treatment induces a strong
increase in cyclin D1 levels in both MCF-7 ATCC and
MCF-7 NKI cells. No significant differences in cyclin D1
induction were observed in the three MCF-7 strains (fig-
ure 2B). Taken together, these results indicate that the dif-
ferences in growth response upon E2 treatment of the
MCF-7 strains are not caused by their ER expression level
or functionality.
Suramin inhibits the E2-induced cell cycle progression in 
E2-responsive MCF-7 cells
To investigate whether E2 can induce cell cycle progres-
sion in MCF-7 ATCC and NKI cells without subsequent
activation of the IGF type I receptor, a DNA synthesis
assay was performed in which 200 µg/ml suramin was
added to the cells one hour prior to stimulation with IGF-Cancer Cell International 2003, 3 http://www.cancerci.com/content/3/1/10
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I, E2 or the combination of both hormones. Suramin is an
anti-tumor agent inhibiting the proliferation of a variety
of human cancer cell lines cultured in vitro [12–15].
Suramin acts extracellularly by interfering with the bind-
ing of growth factors to their receptors [16], including sev-
eral which are known to be involved in tumor growth or
development, like IGF-I [17], and TGFβ [18].
We find that IGF-I-induced incorporation of 3H-TdR is
completely inhibited in all three MCF-7 cell lines, when
the cells are preincubated with suramin (figure 3). Sur-
prisingly, preincubation with suramin also completely
abolishes E2-induced DNA synthesis in all three MCF-7
laboratory strains. These results suggest that activation of
a suramin-sensitive receptor is essential for E2-induced
cell cycle progression.
Blocking IGF-RI with αIR3 antibody inhibits E2-induced 
cell cycle progression in E2-responsive MCF-7 cells
To test whether E2-responsiveness is dependent on IGF-
signaling, the IGF-RI was blocked by the addition of 1 µg/
ml αIR3 antibody to the culture medium, which prevents
binding of IGF-I and -II to the receptor. Figure 4 shows
that IGF-I-induced 3H-TdR incorporation is completely
inhibited in all three strains of MCF-7 treated with αIR3.
However, also the effect of E2 on 3H-TdR incorporation is
reduced to levels comparable to the incorporation in
untreated serum-starved cells. This shows that all three
Effect of IGF-I and E2 on the induction of DNA-synthesis in the MCF-7 strains Figure 1
Effect of IGF-I and E2 on the induction of DNA-synthesis in the MCF-7 strains. Serum-starved cells grown in 24-
wells plates were given no mitogens (-), 20 ng/ml of IGF-I (I(20)), 2 ng/ml of IGF-I (I(2)), 2 ng/ml of IGF-I in combination with 1 nM 
E2 (I(2)E2), or 1 nM E2 (E2) and were harvested after 30 h. 3H-thymidine (2 µCi/ml) was added to the culture 6 h before har-
vesting. Indicated values are means of triplicate measurements, and were normalized for the incorporation induced by 20 ng/ml 
of IGF-I (100%).
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MCF-7 strains loose their E2-responsiveness when IGF-RI
signaling is blocked.
The observed inhibition of DNA synthesis theoretically
might be due to toxicity of the antibodies added to the
cells. To exclude this possibility, the specificity of inhibi-
tion was examined by determining whether other signal-
ing pathways are still intact in antibody treated cells. To
this end, the TPA-induced synthesis of the CKI p21cip1/waf1
protein was studied on Western blot. TPA induces the syn-
thesis of p21cip1/waf1 via activation of the ERK pathway
independent of IGF-RI [19]. A moderate elevation of
p21cip1/waf1 levels is also observed when MCF-7 cells are
treated with mitogenic amounts of IGF-I [20].
Figure 5 shows that the addition of 100 ng/ml of TPA to
the medium induces expression of p21cip1/waf1. IGF-I (20
ng/ml) also clearly results in higher p21cip1/waf1 levels.
αIR3 is able to totally block the upregulation of p21cip1/
waf1 induced by IGF-I, but does not inhibit the stimulation
of p21cip1/waf1 expression by TPA. These results show that
the inhibition of E2-induced DNA synthesis in E2-respon-
sive MCF-7 cells by αIR3 is a result of specific inhibition
of IGF-RI signaling.
MCF-7 ATCC and MCF-7 NKI cells secrete a factor that 
makes them more sensitive to E2-treatment
In view of the fact that activation of the IGF-RI is impor-
tant for E2-induced cell cycle progression in MCF-7 ATCC
and MCF-7 NKI cells, we investigated the possibility of
autocrine stimulation of the IGF-RI in these MCF-7
strains. To this end, we studied the effect of conditioned
media on the E2-responsiveness of the MCF-7 strains in a
DNA-synthesis assay. MCF-7S, ATCC and NKI cells were
seeded in 162 cm2 culture flasks and incubated in serum-
free, estrogen-free medium for two days, after which the
conditioned media were collected. For the DNA-synthesis
assay, MCF-7S, MCF-7 ATCC and MCF-7 NKI cells were
seeded in 24 wells plates, and serum-starved for 24 h.
Prior to stimulation the serum-free medium on the three
MCF-7 strains was replaced by the conditioned media, or
by fresh serum-free medium as a control. After 15 min-
utes, no mitogens, IGF-I (2 or 20 ng/ml), 1 nM E2 or the
combination of 1 nM E2 and 2 ng/ml IGF-I were added to
the media. 24 h later, 3H-TdR was added for a 6 h period,
after which the cells were harvested.
Figure 6 shows the effect of the conditioned media on the
MCF-7S cells. In untreated steroid- and serum-free
medium, MCF-7S cells are not triggered to progress
through the cell cycle by addition of E2. Culturing the
cells in conditioned medium from the MCF-7S cell line
has no significant effect on the 3H-TdR incorporation
induced by any of the hormone treatments. However,
when E2 is administered together with conditioned
medium from MCF-7 ATCC or MCF-7 NKI, the cells
progress through S-phase as is demonstrated by elevated
incorporation of 3H-TdR in these cells.
Also in the MCF-7 ATCC cell line, the conditioned media
from MCF-7 ATCC and MCF-7 NKI, but not the condi-
tioned medium of MCF-7S, induce additional 3H-TdR
incorporation in cells treated with E2 when compared to
cells incubated in fresh serum-free medium with E2. In
MCF-7 ATCC, incubation in the conditioned media from
the two E2-inducible cell lines leads to a higher incorpo-
ration in untreated and in IGF-I (2 ng/ml) treated cells.
This increase is less pronounced in the MCF-7S cell line
(figure 6).
In MCF-7 NKI cells, the conditioned media have no signif-
icant effect on the amount of incorporation induced by
E2, but they do stimulate 3H-TdR incorporation in
untreated and in IGF-I (2 ng/ml) stimulated cells (figure
6). These results suggest that the MCF-7 ATCC and MCF-7
NKI cells secrete a factor into the medium that activates
the IGF-RI and synergizes with E2 to induce cell cycle pro-
gression in all three strains of MCF-7.
A Expression of ERα in MCF-7S, MCF-7 ATCC, and MCF-7  NKI Figure 2
A Expression of ERα in MCF-7S, MCF-7 ATCC, and 
MCF-7 NKI. Serum-starved MCF-7S cells were grown in 6-
wells plates, and were lysed. Levels of ERα were analyzed by 
Western blotting. B Induction of cyclin D1 gene expres-
sion in MCF-7S, MCF-7 ATCC, and MCF-7 NKI by E2. 
Serum-starved MCF-7S cells were grown in 6-wells plates, 
and were given no mitogens (-), or 1 nM E2 (E2). The cells 
were lysed after 6 h. Levels of cyclin D1 were analyzed by 
Western blotting.Cancer Cell International 2003, 3 http://www.cancerci.com/content/3/1/10
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Effect of suramin on the induction of DNA-synthesis by IGF-I and E2 in the three MCF-7 strains Figure 3
Effect of suramin on the induction of DNA-synthesis by IGF-I and E2 in the three MCF-7 strains. Serum-starved 
cells were grown in 24-wells plates, and were preincubated for 1 hour with 200 µg/ml suramin before stimulation with 
mitogens. Cells were given no mitogens (-), 20 ng/ml of IGF-I (I(20)), 2 ng/ml of IGF-I (I(2)), 2 ng/ml of IGF-I in combination with 
1 nM E2 (I(2)E2), or 1 nM E2 (E2) and were harvested after 30 h. 3H-thymidine (2 µCi/ml) was added to the culture 6 h before 
harvesting. Indicated values are means of triplicate measurements. The values were normalized for the incorporation induced 
by 20 ng/ml of IGF-I (100%).
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Effect of an IGF-RI blocking antibody on the induction of DNA-synthesis by IGF-I and E2 in the three MCF-7 strains Figure 4
Effect of an IGF-RI blocking antibody on the induction of DNA-synthesis by IGF-I and E2 in the three MCF-7 
strains. Serum-starved cells were grown in 24-wells plates, and were preincubated for 1 hour with 1 µg/ml of αIR3 antibody 
before stimulation with mitogens. Cells were treated with no mitogens (-), 20 ng/ml of IGF-I (I(20)), 2 ng/ml of IGF-I (I(2)), 2 ng/
ml of IGF-I in combination with 1 nM E2 (I(2)E2), or 1 nM E2 (E2) and were harvested after 30 h. 3H-thymidine (2 µCi/ml) was 
added to the culture 6 h before harvesting. Indicated values are means of triplicate measurements. The values were normalized 
for the incorporation induced by 20 ng/ml of IGF-I (100%).
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Discussion
MCF-7S cells do not proliferate upon addition of only E2
(1 nM) to serum-free medium. Other strains of MCF-7,
here indicated as MCF-7 ATCC and MCF-7 NKI, which
were tested under identical conditions as MCF-7S, do
respond to E2-treatment. We have shown that that the
observed differences in growth response upon E2-treat-
ment of the MCF-7 strains are not caused by differences in
ER expression level or functionality.
The effect of E2 on the incorporation of 3H-TdR is com-
pletely inhibited by suramin-preincubation in all three
cell lines to levels lower than background incorporation
in untreated cells. More specifically, we have shown that
the induction of DNA-synthesis by E2 in all three cell lines
could be blocked completely by incubating the cells with
1 µg/ml of αIR3 antibody, which binds to the IGF-RI and
thereby inhibits the binding of ligand. From this we
conclude that E2-induced DNA synthesis in MCF-7 cells is
dependent on IGF-RI signaling.
Our results indicate that the E2-responsive strains, MCF-7
ATCC and MCF-7 NKI, autonomously activate their IGF-
IR, and that this activation is required for their response to
E2. Since endogenous production of growth factors is a
common feature of many tumor cells, we investigated
whether the two E2-responsive MCF-7 strains secrete an
autocrine factor capable of activating their IGF-RI. We
demonstrated that E2-insensitive cells become E2-sensi-
tive when challenged with conditioned medium of E2-
sensitive cells. This suggests that E2-sensitive cells secrete
an autocrine factor capable of activating the IGF-RI.
Differences in the levels of production of IGF-IR agonists
by the breast cancer cells may explain the differences
observed in the E2-sensitivity of the three MCF-7 strains.
Van der Burg et al., using a sensitive bioassay, could not
detect any IGF-I or -II production in MCF-7S cells [21].
Other reports indicate expression of IGFs by certain MCF-
7 strains. The majority of reports studying this issue report
the absence of detectable IGF-I expression in MCF-7
[22,23]. Expression of IGF-II mRNA has been detected by
Northern blot analysis and RNase protection assays
[24,25]. After removal of the binding proteins,
concentrations between 4.7 and 14.4 ng/ml per 107 MCF-
7 cells of IGF-II protein has been found in conditioned
medium depending on the technique used (RIA and radi-
oreceptor assays) [25]. Significantly, Yee et al. observed
that IGF-II expression by MCF-7 cells increases with the
passage number of the cell culture [24]. This observation
suggests that the factor secreted by E2-sensitive cells may
be IGF-II. IGF-II has been shown to induce a mitogenic
response in a variety of breast cancer cell lines. It has been
found to be slightly less potent than IGF-I, since 2–4 times
higher concentrations IGF-II are needed for equal
responses in a DNA synthesis assay [25,26]. Even so, the
concentrations reportedly present in the conditioned
medium of MCF-7 cells [25] are sufficient to synergisti-
cally induce a mitogenic response in MCF-7 cells upon
addition of E2. The reason for the change in IGF-II expres-
sion over time is not clear. The MCF-7 cell line was iso-
lated from a pleural effusion derived from a breast
carcinoma [27], and was shown to consist of several dif-
ferent subpopulations of cells [28]. It is plausible that dur-
ing cultivation of the initially heterogeneous cell line an
IGF-II-expressing cell type is naturally selected because of
its growth advantage over non-growth-factor expressing
cells.
MCF-7S cells, in contrast to other laboratory MCF-7
strains, are almost completely growth arrested in G0/G1
phase of the cell cycle by serum deprivation in estrogen-
free medium, without the need for estrogen antagonists or
other inhibitors to reach quiescence. We have found that
the MCF-7S cells show this characteristic for about 25 to
30 passages, after which the cells start to grow more rap-
idly and do no longer show complete growth arrest upon
serum withdrawal. Furthermore, during cell culture the
cells become more IGF independent and significant pro-
liferation can be induced by the sole addition of E2 to the
serum-free medium. Endogenous expression of IGF-I or
IGF-II by E2-sensitive MCF-7 strains could account for
Effect of an IGF-RI blocking antibody on the induction of p21  Cip1/Waf1 Figure 5
Effect of an IGF-RI blocking antibody on the induc-
tion of p21 Cip1/Waf1 Serum-starved MCF-7S cells were 
grown in 6-wells plates, and were preincubated for 1 hour 
with 1 µg/ml of αIR3 antibody before stimulation with 
mitogens. They were given no mitogens (-), 20 ng/ml of IGF-I 
(I(20)), or 100 ng/ml of TPA (TPA) and were lysed after 4 h. 
Levels of p21Cip1/Waf1 were analyzed by Western blotting.Cancer Cell International 2003, 3 http://www.cancerci.com/content/3/1/10
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Effect of conditioned serum-free media from MCF-7 cells on the induction of DNA-synthesis by IGF-I and E2 in the three MCF- 7 strains Figure 6
Effect of conditioned serum-free media from MCF-7 cells on the induction of DNA-synthesis by IGF-I and E2 in 
the three MCF-7 strains. Conditioned media (CM) were generated by incubating MCF-7S, ATCC and NKI cells in serum-
free, estrogen-free medium for two days, after which the medium was collected and centrifuged to spin down the cell debris. 
Serum-starved cells were grown in 24-wells plates, and were incubated in normal serum-free medium (indicated as [-] in the 
figure legend) or in the conditioned serum-free media (indicated as CM MCF-7S, CM MCF-7ATCC, or CM MCF-7 NKI). The 
cells were given no mitogens (-), 20 ng/ml of IGF-I (I(20)), 2 ng/ml of IGF-I (I(2)), 2 ng/ml of IGF-I in combination with 1 nM E2 
(I(2)E2), or 1 nM E2 (E2) and were harvested after 30 h. 3H-thymidine (2 µCi/ml) was added to the culture 6 h before harvest-
ing. Indicated values are means of triplicate measurements. The values were normalized for the incorporation induced by 20 
ng/ml of IGF-I (100%).
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their observed E2 inducible growth, independent of IGF-I
addition. The change in E2-responsiveness of MCF-7S
may indicate that prolonged growth in tissue culture trig-
gers the production of IGF. Alternatively, IGF-producing
cells that were already present in the original culture gain
a growth advantage and gradually overgrow the non-IGF-
producing cells. In conclusion, the differential response of
different MCF-7 strains to E2 and IGF-I may well be due
to differences in the individual IGF-expression status in
these strains. Using RT-PCR, we found than none of the
MCF-7 strains produce IGF-I. However, in all three of the
cell lines IGF-II mRNA could be detected (data not
shown). Thus, IGF-II may well be the autocrine factor
involved in regulation of the response to E2.
In conclusion, we have shown that E2-responsiveness of
MCF-7 cells is dependent on the secretion of an autocrine
factor activating the IGF-IR. All three strains of MCF-7
breast cancer cells investigated do not respond to E2 if the
IGF-RI-pathway is blocked. Generally, breast cancer ther-
apy is targeted at inhibiting estrogen action. This study
suggests that inhibition of IGF-action in combination
with anti-estrogen-treatment may provide a more effective
way in treatment or even prevention of breast cancer.
Methods
Reagents
Anti-p21CIP1/WAF1 (H-164) was purchased from Santa Cruz
Biotechnology (Santa Cruz, CA). IGF-I was from GroPep
(Adelaide, Australia). Aprotinin, E2, sodium selenite,
suramin, and TPA were purchased from Sigma (St. Louis,
MO). Albumin, bovine fraction V (BSA, Catalogue
number 840533), Na3VO4 and transferrin were from ICN
Biomedicals, Inc. (Aurora, OH). The αIR3 antibody was a
kind gift of Dr. S. van Buul-Offers from the Department of
Pediatric Endocrinology, UMC Utrecht, The Netherlands.
Cell culture
The MCF-7 human breast cancer cell lines were cultured in
Dulbecco's Minimal Essential Medium/Ham's F12
medium (1:1), supplemented with 10% fetal calf serum,
300 µg/ml of glutamine, 100 IU/ml of penicillin and 100
µg/ml of streptomycin. Cell cultures of 40–60% conflu-
ence were used for experiments. Prior to experiments,
MCF-7 cells were cultured for 24 h in phenol red-free
medium containing 5% dextran-coated charcoal-treated
serum, followed by an incubation in phenol red-free,
serum-free medium, supplemented with 0.2% bovine
serum albumin (BSA), 10 µg/ml of transferrin and 30 nM
sodium selenite for at least 24 h.
3H-Thymidine incorporation
Assays were performed in 24-well plates. Serum-starved
cells were stimulated with IGF-I, E2, or a combination of
the two and after 24 h of incubation 3H-labeled thymi-
dine (2 µCi/ml) was added. 30 h after the addition of the
stimuli, cells were fixed with 10% trichloroacetic acid,
washed in PBS and lysed in 0.1 M NaOH, followed by liq-
uid scintillation counting.
Western blotting
Experiments were performed in 6-well plates. After stimu-
lation, cells were washed with ice-cold PBS and lysed in
lysis buffer (50 mM Tris-HCl, pH 6.8, 2% SDS, 10% glyc-
erol). Lysates were boiled for 5 min and protein concen-
trations were determined using the BCA protein assay
(Pierce, Rockford, IL). After addition of 0.1% bromophe-
nol blue and 5% β-mercaptoethanol to the samples, equal
amounts of protein (5–50 µg) were size-separated on a
SDS-polyacrylamide gel and transferred to nitrocellulose.
The membrane was stained with Ponceau S (Sigma) to
check for equal loading and blocked with 2–3% non-fat
milk or 0.5–2% BSA in TBST (150 mM NaCl, 10 mM Tris-
HCl pH 8.0, 0.2% Tween 20) for 1 h. Incubation with the
primary antibody was performed overnight at 4°C in 0.1
× blocking solution. The membrane was washed in TBST
and exposed to horseradish peroxidase-coupled second-
ary antibody for 1 h in TBST. For detection the Western
Blot Chemiluminescence Reagent Plus system (NEN Life
Science Products Inc., Boston, MA) was used.
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